Author:
Müller Matthias J.,Benkert Otto
Publisher
Springer Berlin Heidelberg
Reference15 articles.
1. Ben-Sheetrit J, Hermon Y, Birkenfeld S et al (2023) Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry 22(1):15
2. Briken P, Matthiesen S, Pietras L et al (2020) Estimating the prevalence of sexual dysfunction using the new ICD-11 guidelines. Dtsch Ärztebl Int 117(39):653–658
3. Chokka PR, Hankey JR (2018) Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol 8(1):13–23
4. Clayton AH, Kingsberg SA, Goldstein I (2018) Evaluation and management of hypoactive sexual desire disorder. Sex Med 6(2):59–74
5. Corona G, Rastrelli G, Burri A et al (2016a) The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf 15(2):237–247